Jack Cuzick, PhD, a professor of epidemiology at Wolfson Institute of Preventive Medicine, discusses how to determine if a woman is at high risk of developing breast cancer and which of these women should consider taking tamoxifen as a preventative measure.
Jack Cuzick, PhD, a professor of epidemiology at Wolfson Institute of Preventive Medicine, discusses how to determine if a woman is at high risk of developing breast cancer and which of these women should consider taking tamoxifen as a preventative measure.
Cuzick says the three areas that are assessed to determine if someone is at high risk of developing breast cancer are family history, breast density and benign breast lumps. Two breast cancers in the family, or a mother or sister who had breast cancer under the age of 50, more than doubles the risk of developing breast cancer, Cuzick says. Benign breast lumps, such as a-typical hyperplasia or any hyperplastic lesion, carry a 4-to-5-fold risk of developing breast cancer. Women with dense breasts have 4-times the risk of developing breast cancer compared to those who do not have dense breasts, Cuzick says.
Everyone that falls into this group, especially women with benign breast lumps, should be offered tamoxifen as a preventative measure, Cuzick says. By using the mammogram as a chance to review risk of breast cancer in addition to screening for cancer, physicians and patients have a chance to discuss available options that are appropriate.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.